Lupin announced that it has received approval for its Ethacrynic Acid Tablets USP, 25 mg, from the United States Food and Drug Administration (USFDA).
Lupin's Ethacrynic Acid Tablets USP, 25 mg, is the generic version of Edecrin® Tablets, 25 mg, of Bausch Health
Americas, Inc.
Ethacrynic Acid Tablets USP (RLD: Edecrin® Tablets) had annual sales of approximately USD 24 million in the US (IQVIA
MAT June 2019).